Cardiovascular Systems, Inc. (NASDAQ:CSII) Files An 8-K Results of Operations and Financial Condition

Cardiovascular Systems, Inc. (NASDAQ:CSII) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Story continues below

On August 2, 2017, Cardiovascular Systems, Inc. (the “Company”) issued a press release regarding the Company’s financial results for its fourth fiscal quarter ended June 30, 2017. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

Item 2.02. Financial Statements and Exhibits.

Exhibit

Number

Description

99.1

Press Release dated August 2, 2017.


Cardiovascular Systems Inc Exhibit
EX-99.1 2 ex9914thqtrrelease.htm EXHIBIT 99.1 Exhibit             CARDIOVASCULAR SYSTEMS,…
To view the full exhibit click here

About Cardiovascular Systems, Inc. (NASDAQ:CSII)

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

An ad to help with our costs